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Heart failure with preserved ejection fraction (HFPEF) is
becoming the dominant form of heart failure in developed
countries (1). Yet, there remain fundamental gaps in our
understanding of the pathophysiology of HFPEF (2), and
we still do not have evidence-based therapies to reduce
morbidity and mortality in HFPEF.
See page 1778
The study by Akiyama et al. (3), in this issue of the
Journal, highlights a potential novel target in HFPEF. In
this observational hospital-based study of 321 patients with
HFPEF and 173 age-, sex-, and comorbidity-matched
controls, endothelial function was assessed using reactive
hyperemia peripheral arterial tonometry. Endothelial dys-
function (defined by a reactive hyperemia index below the
median value of 0.49) was independently associated with
HFPEF, as were higher body mass index and lower glo-
merular filtration rate. In HFPEF, endothelial dysfunction
predicted cardiovascular events over a mean follow-up of 20
months, independently of clinical (age, diabetes, hospital-
ization, New York Heart Association status), echocardio-
graphic (E/e’, ejection fraction), and neurohormonal (brain
natriuretic peptide) factors. Of note, the study population
consisted of patients referred to 2 tertiary centers in Japan,
was more predominantly male (50%), and had better out-
comes than observed in Western cohorts (1). Whether this
was due to selection bias or true ethnic differences could not
be ascertained. Nonetheless, the strong prognostic signifi-
cance of endothelial dysfunction in HFPEF suggested that
the association was not merely a passive observation, but
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to the pathophysiology and progression of HFPEF.
Endothelial Dysfunction
The endothelium plays an obligatory role in cardiovascular
homeostasis by regulating cardiac function and vasomotor
tone, adjusting vascular permeability, and preserving blood
fluidity (4). Endothelial dysfunction is clinically assessed as
a deficient vasodilatory response to various stimuli, indicat-
ing impaired endothelium-mediated nitric oxide (NO) bio-
availability. In the study by Akiyama et al (3), the stimulus
used was the surge of blood flow after release of brachial
artery cuff occlusion (endothelium-dependent flow-
mediated dilatation), and the hyperemic response was mea-
sured in the peripheral vasculature. This methodology is
simple and noninvasive, offering the potential for wide-
spread clinical application, but it provides only a narrow
view of overall endothelial function. A comprehensive
assessment of endothelial function requires consideration of
the endothelium as an integrated system involving not only
the peripheral vasculature of the systemic circulation but
also the central circulation, including the cardiac (myocar-
dial capillary and endocardial) and pulmonary vascular
endothelia (Fig. 1A) (4). The findings of Akiyama et al. (3)
may be viewed as a mere reflection of a more general
dysfunction of the entire endothelial system in heart failure,
because these peripheral vascular measurements will genu-
inely contribute to our insights into the pathophysiology of
HFPEF only if placed in such a broader context.
Cardiovascular Risk Factors
and Endothelial Dysfunction
When viewed as a single system integrated within other
organ systems of the body, the endothelium forms the first
point of contact between circulating blood-borne factors
and adjacent organ tissues. In the presence of cardiovascular
risk factors such as diabetes, dyslipidemia, and hypertension,
redox imbalances induce oxidative stress that causes endo-
thelial dysfunction (5), even in the absence of end-organ
damage. Akiyama et al. (3) matched their patients and
controls for diabetes and hypertension, but still found more
endothelial dysfunction in patients with HFPEF, who were
notably more obese than controls. Obesity is associated with
marked endothelial dysfunction that has recently been
shown to be related to increased activity of the proinflam-
matory cytokine tumor necrosis factor- (promoting super-
oxide generation and reducing NO bioavailability in visceral
adipose vasculature) (6). HFPEF is increasingly recognized
as an inflammatory condition, mediated in large part by
obesity (7). The higher levels of high-sensitivity C-reactive
protein in the HFPEF group of the study by Akiyama et al.
(3) support this concept.
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Although there are ample experimental and clinical data
showing that both peripheral and central endothelial dys-
function contribute to the pathogenesis of heart failure (8),
most of this evidence pertains to heart failure with reduced
ejection fraction. In skeletal muscle, endothelial dysfunction
in both conductive and resistance vessels may explain
exercise intolerance—the cardinal manifestation of heart
failure irrespective of ejection fraction. In HFPEF, Borlaug
et al. (9) found a high prevalence of endothelial dysfunction
Figure 1 The Endothelial System in HFPEF
The cardiovascular endothelial system integrates the peripheral vascular endo-
thelium (VE) with the central cardiac endothelium (consisting of coronary VE,
myocardial capillary endothelium, and endocardial endothelium) and pulmonary
VE. Modified with permission from Brutsaert DL. Cardiac endothelial-myocardial
signaling: its role in cardiac growth, contractile performance, and rhythmicity.
Physiol Rev 2003;83:59–115. (A) The endothelium is at the interface between
circulating cardiovascular factors and underlying organ tissues. Oxidative stress
causes endothelial activation, endothelial dysfunction, and organ-level dysfunc-
tion that may be observed in patients with heart failure with preserved ejection
fraction (HFPEF) (red italics). (B) The relative contribution of endothelial dys-
function to the pulmonary versus systemic circulations may differ. Considering
hemodynamic factors of pressure (P), volume (V), and flow (F), the predomi-
nantly flow-endothelium–dependent pulmonary circulation (blue) may be more
susceptible to shear stress and endothelial dysfunction compared with the pre-
dominantly pressure-load–dependent systemic circulation (red). LV  left ven-
tricle; RV  right ventricle.and blunted exercised-induced augmentation in peripheralblood flow in association with reduced exercise capacity.
Likewise, Akiyama et al. (3) observed poorer New York
Heart Association status in those with impaired endothelial
function, underscoring the functional significance of endo-
thelial dysfunction in HFPEF. Furthermore, endothelial
dysfunction may affect the renal vasculature (10). The extent
to which renal vascular endothelial dysfunction contributed
to the lower glomerular filtration rates in patients with
HFPEF compared with matched controls in the study by
Akiyama et al. (3) deserves further study.
Central Cardiac Endothelium
Beyond endothelial cells in various peripheral organs, en-
dothelial cells in the heart warrant consideration for their
role in HFPEF (4). These include endothelial cells of the
coronary vessels, but more important of the intramyocardial
capillaries and endocardium where endothelial cells directly
communicate with subjacent cardiomyocytes. The contribu-
tion of the cardiac endothelium, in conjunction with the
pulmonary vascular endothelium (Fig. 1A), is of critical
importance because this represents the largest endothelial
surface of the body and serves as the greatest single source of
endothelial mediators (4). Indeed, in experimental post-
infarction settings, both cardiac (11) and pulmonary vascu-
lar (12) endothelial dysfunction have been shown to con-
tribute to the development of heart failure. In the setting of
HFPEF, however, data are scarcer. The key risk factors for
HFPEF, namely, hypertension and diabetes, are associated
with evidence of endocardial and myocardial capillary en-
dothelial abnormalities in experimental models (13,14), and
these abnormalities may explain the impaired left ventricular
relaxation in pressure-overload hypertrophy (15). The cor-
onary endothelium has been shown to modulate left ventric-
ular diastolic function via paracrine effects in healthy humans
and patients post-transplant (16). More work is needed to
better understand how cardiac endothelial dysfunction contrib-
utes to the pathophysiology of human HFPEF.
Systemic Versus Pulmonary Circulation
Combined ventricular and vascular stiffening, involving
both the systemic and pulmonary circulations, is known to
play a role in the pathophysiology of HFPEF (17,18). In the
systemic circulation, endothelial dysfunction, detectable in
healthy individuals with normal brachial blood pressure, is
associated with increased central pulse pressure and systemic
arterial stiffening (19). This suggests that systemic endothe-
lial dysfunction may be a primary phenomenon in the
development of frank systemic hypertension and its patho-
physiologic consequences of increased left ventricular wall
stress, hypertrophy, diastolic dysfunction, and HFPEF. In
the pulmonary circulation, endothelial dysfunction has sim-
ilarly been detected as an early event leading to the devel-
opment of pulmonary hypertension in the setting of exper-
imental heart failure (12). The presence of pulmonary
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the common substrate underlying parallel changes in the
systemic and pulmonary circulations, the relative contribu-
tions of endothelial dysfunction in the 2 circulations may
differ: The pulmonary circulation, being primarily flow-
driven in contrast to the pressure-driven systemic circula-
tion, may be more susceptible to the influence of shear stress
and endothelial dysfunction (Fig. 1B).
Conclusions
A significant pathophysiologic role of endothelial dysfunc-
tion in HFPEF, as supported by data from Akiyama et al.
(3), suggests that endothelial dysfunction may be a potential
therapeutic target. Indeed, many of the actions of
endothelium-derived NO are attributable to activation of
the cyclic GMP pathway—a pathway targeted by com-
pounds such as sildenafil and LCZ696, which are currently
being tested in therapeutic trials in HFPEF. Results of
these trials are eagerly anticipated and may shed more light
on the importance of endothelial function in HFPEF.
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